drugset / Trial / NCT00043368

PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)

NCT00043368

Phase 2 Completed 31 enrolled Pfizer
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This protocol allows patients who completed Coley oncology studies using PF-3512676 (CPG 7909) Injection to continue receiving the treatment until disease progression.

Timeline

Start
2002-09
Primary completion
2007-06
Completion
2007-06

Drugs

EvaluationDrugModalityDoseRoute
Subject agatolimod Oligonucleotide (other) 0.01 mg/kg Intravenous
Subject agatolimod Oligonucleotide (other) 0.04 mg/kg Intravenous
Subject agatolimod Oligonucleotide (other) 0.16 mg/kg Intravenous
Subject agatolimod Oligonucleotide (other) 0.2 mg/kg Intravenous
Subject agatolimod Oligonucleotide (other) 0.28 mg/kg Intravenous
Subject agatolimod Oligonucleotide (other) 0.32 mg/kg Intravenous
Subject agatolimod Oligonucleotide (other) 6 mg Intravenous
Subject agatolimod Oligonucleotide (other) 10 mg Intravenous
Subject agatolimod Oligonucleotide (other) 40 mg Intravenous